Insulin aspart
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Insulin aspart and local guidelines before prescribing.
Mechanism
Rapid-acting insulin analogue activating insulin receptors.
Uses
Mealtime and correction insulin in type 1 and type 2 diabetes.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Hypoglycaemia, weight gain, lipohypertrophy, injection-site reactions.
Interactions
Beta-blockers mask hypoglycaemia symptoms; corticosteroids and thiazides raise glucose; alcohol.
Contraindications and cautions
Hypoglycaemia
Monitoring
Glucose, HbA1c
Pregnancy and breastfeeding
Safe
Renal and hepatic impairment
Requirements fall in renal impairment
Overdose and reversal
Glucose and monitoring until recovered
Special advice
Inject just before or after eating; rotate sites; sick-day rules; dose by carbohydrate counting.
More from the textbook: uses, cautions and other points
- Rapid-acting analogues | Insulin aspart (NovoRapid, Fiasp), lispro (Humalog), glulisine (Apidra). Onset 10–15 min, peak 1–2 h, lasts 3–5 h. Injected just before meals (bolus); used in pumps
Endocrinology: Diabetes - Types : Type Examples Use Rapid-acting analogue Insulin aspart (NovoRapid, Fiasp), lispro (Humalog) With meals (bolus); correction doses; insulin pumps Short-acting soluble Actrapid, Humulin S IV infusions (VRIII, DKA), meals Intermediate Isophane (Humulin I, Insulatard) Once or twice daily basal; type 2 diabetes; …
Clinical pharmacology and prescribing: High-risk drugs, therapeutic drug monitoring, IV fluids and antimicrobial prescribing - Rapid-acting analogue | Insulin aspart (NovoRapid, Fiasp), lispro (Humalog) | With meals (bolus); correction doses; insulin pumps
Clinical pharmacology and prescribing: High-risk drugs, therapeutic drug monitoring, IV fluids and antimicrobial prescribing